Weight loss drug Ozempic linked to lower depression and anxiety risk
People with diabetes have a higher risk of depression and anxiety. GLP-1 receptor agonists are approved for treating diabetes and obesity, but research is still unclear on whether they improve or worsen anxiety, depression, or self-harm risk. A new study examined whether people already diagnosed with depression, anxiety, or both had a higher risk of worsening mental illness after being prescribed diabetes medications, including GLP-1 receptor agonists.
- Core message: GLP-1 medications, especially semaglutide, the active ingredient in Ozempic and Wegovy, were linked with better mental health outcomes in people who already had depression or anxiety and were also using diabetes medications. The main finding is that these drugs may do more than improve blood sugar and support weight loss. They may also be associated with fewer serious mental health setbacks.
- Primary argument: Because diabetes, obesity, depression, and anxiety often overlap, researchers wanted to know whether GLP-1 drugs might affect mental health. They studied Swedish national health records from 2009 to 2022 and followed more than 95,000 people diagnosed with depression or anxiety. Of these, 22,480 had used GLP-1 medications.
- What they compared: Researchers compared periods when the same people were taking GLP-1 medications with periods when they were not taking them. This helped reduce some differences between people, because each person partly served as their own comparison.
- Key findings: Semaglutide use was linked to a 42% lower risk of psychiatric hospital care or sick leave due to mental health problems. The risk was 44% lower for depression-related outcomes, 38% lower for anxiety-related outcomes, and 47% lower for substance-use-related outcomes.
- Other findings: Liraglutide showed a smaller benefit, with an 18% lower risk. Other GLP-1 drugs, including exenatide and dulaglutide, did not show the same clear reduction. GLP-1 drugs as a group were also linked with reduced self-harm risk.
- Simple takeaway: This study suggests Ozempic-like medications may support both physical and mental health, but the study was observational. It shows a strong association, not proof that the medication directly caused the mental health improvement. Controlled clinical trials are still needed.
https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(26)00014-3/fulltext
